Wolters Kluwer Celebrates the 25th Anniversary of UpToDate with Launch of 25th Specialty, Anesthesiology
Wolters Kluwer Health announced today that UpToDate ®, the acclaimed evidence-based clinical decision support (CDS) resource, is commemorating its 25 th anniversary with the launch of its 25 th clinical specialty, anesthesiology.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171005005691/en/
In 1992, Dr. Burton “Bud” Rose, a renowned nephrologist and medical textbook author, created UpToDate in the basement of his house. Initially a nephrology-focused disease reference tool accessed via floppy disk, UpToDate has since grown to become one of the most trusted and indispensable clinical resources used by clinicians around the world to diagnose and treat patients.
Denise Basow, MD, President and CEO of Clinical Effectiveness at Wolters Kluwer, said, “Dr. Bud Rose’s real genius was to say, ‘Instead of writing about a particular disease, let’s write about the specific clinical questions that a clinician has, apply the best evidence to answer those questions, and then make very specific recommendations for care.’” She adds, “Today with UpToDate, we are changing more than 300,000 medical decisions every day in more than 180 countries.”
Over the past 25 years, UpToDate has grown as a vital clinical resource to include more than 10,500 clinical topics in 25 specialties. A clinical faculty of more than 6,500 physician authors, editors, and peer-reviewers from 53 countries apply their deep clinical domain expertise to critically evaluate available medical literature and produce original content in a succinct, searchable format that can be quickly and easily accessed at the point of care. Today, more than 1.3 million clinicians in 187 countries consult UpToDate via the website and mobile app, viewing more than 32 million topics per month.
Watch our special UpToDate 25th-anniversary video: https://youtu.be/23GYp2uWaUg
The Latest Evidence to Support the Anesthesiology Specialty
In concert with its 25th anniversary, UpToDate introduces its 25th specialty, anesthesiology. This new specialty covers anesthesia topics related to surgical procedures and other interventions, pain management, opioid avoidance, blood transfusion, and postoperative critical care. Led by Editors-in-Chief, Roberta Hines, MD; Stephanie B. Jones, MD; and Lena S. Sun, MD, the topics in the specialty are written to assist anesthesiologists and nurse anesthetists with finding the best evidence to manage perioperative care for complex patients undergoing common and uncommon procedures, including preoperative consultation, intraoperative anesthetic management, postoperative acute care, and optimal pain management. The new specialty is also a vital resource for general practice clinicians as well as specialists such as surgeons who routinely care for patients together with anesthesiologists.
The specialty’s actionable, evidence-based content is authored, edited and reviewed by 190 world-renowned anesthesiology experts. With 271 topics associated with anesthesiology, UpToDate provides comprehensive coverage complemented by 897 graphics and 96 recommendations that are graded to specify the strength of the recommendations and the quality of their underlying evidence. Additionally, 19 patient education topics provide clinical guidance that can be shared with patients. The specialty’s content will continue to expand in the coming years.
“The practice of anesthesia continues to grow more complex and challenging, as patients with significant medical comorbidities increasingly undergo complicated surgical procedures. As we commemorate a quarter-century of helping clinicians make the best care decisions, we’re committed to supporting anesthesiologists and clinicians in other specialties alike with comprehensive, trustworthy guidance from experts in the field,” said Dr. Basow.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.
Wolters Kluwer | Clinical Effectiveness
André Rebelo, +1 781-392-2411
Public & Analyst Relations Manager, UpToDate
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
First Westinghouse AP1000® Nuclear Plant Sanmen 1 Completes Initial Criticality21.6.2018 23:24 | Tiedote
Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) announced today that the world’s first AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China has successfully completed initial criticality. “Today we completed the final major milestone before commercial operation for Westinghouse’s AP1000 nuclear power plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “We are one step closer to delivering the world’s first AP1000 plant to our customer and the world – with our customers, we will provide our customers in China with safe, reliable and clean energy from Sanmen 1.” Following initial criticality will be connection to the electrical grid. Once plant operations begin at Sanmen 1, it will be the first AP1000 nuclear power plant in operation, offering innovative passive safety system technology, multiple layers of defense and advanced controls for unequaled reliability and safety. Commentin
Westinghouse Loads Fuel in Second AP1000® Nuclear Power Plant21.6.2018 23:07 | Tiedote
Westinghouse Electric Company and its customers, China State Nuclear Power Technology Corporation (SNPTC) and Shangdong Nuclear Power Company Limited (SDNPC) announced today that Haiyang Unit 1, the AP1000 nuclear power plant located in Haiyang, Shandong Province, China, has begun to load fuel. “This is a great day for Westinghouse, our China partners and the nuclear industry. Haiyang Unit 1 continues to demonstrate our ability to deliver safe, innovative solutions for power generation,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. He added, “Westinghouse will continue to deploy AP1000 technology throughout the world and demonstrate our technical leadership in the nuclear energy industry.” Fuel load at Haiyang Unit 1 commenced at 7:36 p.m. (GMT+8) today. Earlier this summer, in preparation for fuel load, Haiyang Unit 1 successfully completed the necessary testing and regulatory reviews conducted by China’s National Nuclear Safety Administration (NNS
Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 201821.6.2018 21:23 | Tiedote
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018. Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and Chief Executive Officer said: “We are thrilled to bring this Phase 3 clinical trial to completion and we now expect to disclose top-line results by October of this year. Our PLEODRUG™ PXT3003 has already shown initial signals of efficacy in our Phase 2 trial in CMT1A. We are hopeful we can bring this much-needed therapy to patients suffering from this debilitating condition, as they currently have limited therapeutic options, mo
Philip Morris International Makes Call to Creative, Media and Communications Communities21.6.2018 21:13 | Tiedote
Philip Morris International Inc. (“PMI”) (NYSE: PM), today announced a bold call to action for the creative, media and communications communities to embrace its ongoing commitment to creating a smoke-free world. As part of this initiative, PMI will offer smoke-free alternatives wherever we can, including heated tobacco products and e-cigarettes, to current smokers in the industry who would otherwise continue to smoke. During a keynote at the PMI Science Lounge at The Cannes Festival of Creativity, SVP of Communications Marian Salzman said, “We are asking the creative community to join us in raising awareness of the potential of science, technology and innovation for those who smoke and the people around them.” The move is part of PMI’s vision to lead the charge towards greater innovation and technology in the tobacco industry, all of which is backed by science. Agencies interested in joining the movement can contact Marian Salzman at firstname.lastname@example.org. “People who smoke deserve in
IBC2018 Announces Cyber Security Forum to Help Media Tackle Cyber Threats21.6.2018 19:30 | Tiedote
IBC2018, the world’s most influential media, entertainment and technology show, today announces a Cyber Security Forum to expand its position as the preeminent cyber security destination for broadcasters and media. The event will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018, which last year attracted more than 57,000 attendees from 170 countries. The Cyber Security Forum is one-day, invitation-only event that will convene Chief Technology Officers, Chief Information Officers, Chief Information Security Officers and Chief Digital Officers within media and broadcasting for a conversation on the challenges and opportunities presented by cyber security for broadcasters. Attendees will discuss how to anticipate the next cyber threat, how to manage a breach and how to prepare for the future of cyber security. The Cyber Security Forum sits alongside the Telco & Media Innovation Forum and Leaders’ Forum as part of IBC’s Exec
Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe21.6.2018 19:23 | Tiedote
Mensia Technologies, french MedTech start up, leads the new booming category of Digital therapeutics with its revolutionary « at home « neurofeedback, to train the brain and cure neuropsy disorders without drugs. Co-founder INRIA-IT2, existing shareholders and now HARA, which are business angels experts in medical device category, joined this fund raise. BPI de Rennes is also part of this tour. Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in Rennes are computing real time signaling softwares. The neurofeedback technique is non invasive, at home and without drugs. MENSIA KOALA treats ADHD, Attention Deficit Disorders with or without Hyperactivity, children and adolescents. This unique medical device is a therapeutic video game on an interactive tablet connected to the brain activity. Children learn to control their attention by exercising 3 times a week during 4 months of treatment. Visual feedback given during the game, allows the children to learn, control and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme